Management of Hypertension in Patients Undergoing Surgery by Aronow, Wilbert S
Touro Scholar 
NYMC Faculty Publications Faculty 
5-1-2017 
Management of Hypertension in Patients Undergoing Surgery 
Wilbert S. Aronow 
New York Medical College 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Cardiology Commons, and the Surgery Commons 
Recommended Citation 
Aronow, W. S. (2017). Management of Hypertension in Patients Undergoing Surgery. Annals of 
Translational Medicine, 5 (10), 227. https://doi.org/10.21037/atm.2017.03.54 
This Editorial is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for 
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, 
please contact daloia@nymc.edu. 
Page 1 of 3
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2017;5(10):227atm.amegroups.com
Editorial
Management of hypertension in patients undergoing surgery
Wilbert S. Aronow
Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
Correspondence to: Wilbert S. Aronow, MD, FACC, FAHA. Professor of Medicine, Cardiology Division, Westchester Medical Center and New York 
Medical College, Macy Pavilion, Room 141, Valhalla, NY 10595, USA. Email: wsaronow@aol.com.
Submitted Feb 05, 2017. Accepted for publication Feb 07, 2017.
doi: 10.21037/atm.2017.03.54
View this article at: http://dx.doi.org/10.21037/atm.2017.03.54
Hypertension is a major risk factor for causing coronary 
events, stroke, heart failure, peripheral arterial disease, 
dissecting aneurysm, chronic kidney disease,  and 
mortality (1-4). Hypertension in the perioperative and 
postoperative period increases cardiovascular events, 
cerebrovascular events, bleeding, and mortality and should 
be controlled prior to major elective noncardiac surgery and 
cardiac surgery (5-7). The higher the blood pressure, the 
greater the risk. A systematic review and meta-analysis of 
30 observational studies found that hypertension increased 
perioperative cardiovascular complications by 35% (8). 
As much as 25% of patients having major non-cardiac 
surgery have perioperative hypertension (9). As much as 
80% of patients having cardiac surgery have perioperative 
hypertension (6,7). Hypertensive comorbidities associated 
with adverse perioperative outcomes include occult 
coronary artery disease (Q waves on the electrocardiogram), 
heart failure, left ventricular hypertrophy, serum creatinine 
higher than 2.0 mg/dL, and cerebrovascular disease (10).
Hypertension is the commonest avoidable medical 
reason for postponing surgery (9). However, there are no 
universally accepted guidelines stating the level of blood 
pressure at which elective surgery should be cancelled (9). 
Increased complications including myocardial infarction, 
myocardial ischemia, dysrhythmias, cerebrovascular events, 
and renal failure have been reported if the preoperative 
diastolic blood pressure is 110 mmHg or higher (11). It has 
been recommended to cancel elective surgery if the systolic 
blood pressure is 180 mmHg or higher or if the diastolic 
blood pressure is 110 mmHg or higher (8,10).
The frequency of acute postoperative hypertension 
has been reported to be between 9% to 64% in patients 
undergoing carotid endarterectomy, 22% to 54% in 
patients undergoing cardiac surgery, 20% in patients 
undergoing elective noncardiac surgery, 33% to 75% in 
patients undergoing abdominal aortic surgery, and 57% to 
91% in patients undergoing intracranial neurosurgery (7). 
Preoperative hypertension is the most determinant in the 
development of postoperative hypertension in patients 
following carotid endarterectomy (12). In a study of 253 
carotid endarterectomies, postoperative hypertension was 
associated with an increase in neurologic morbidity and 
mortality (12). In a study of 2,069 patients undergoing 
elective coronary artery bypass grafting surgery, 29.6% 
had preoperative isolated systolic hypertension (13). The 
patients with preoperative isolated systolic hypertension had 
a 40% increase in perioperative cardiovascular events (13). 
Drugs used for the treatment of hypertension depends 
on associated comorbidities (1-4). For example, patients 
with coronary artery disease should be treated with beta 
blockers and angiotensin converting enzyme inhibitors or 
angiotensin receptor blockers plus thiazide-or thiazide-
like diuretics or calcium channel blockers if additional 
antihypertensive medication is required (1-4,14). The 
blood pressure treatment goal I recommend depends on 
the comorbidities (15). There are no randomized clinical 
trial data showing what the optimal blood pressure should 
be at the time of surgery. On the basis of the available data, 
I favor a blood pressure of less than 130/80 mmHg at the 
time of surgery, especially in older persons (16). 
The 2014 American College of Cardiology/American 
Heart Association guideline on perioperative cardiovascular 
evaluation and management of patients undergoing 
noncardiac surgery recommend perioperative beta blocker 
therapy in patients being treated with beta blockers and 
starting beta blockers in patients with intermediate- or 
high-risk preoperative tests or with a Revised Cardiac Risk 
index of 3 or higher (17). Beta blockers should be initiated 
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more than 1 day prior to surgery (17). Beta blockers should 
not be started on the day of noncardiac surgery because of 
data from the Perioperative Ischemic Evaluation (POISE) 
trial (17,18). The 2014 American College of Cardiology 
guidelines also state that it is reasonable to continue 
angiotensin -converting enzyme inhibitors or angiotensin 
receptor blockers perioperatively (17). Use of angiotensin-
converting enzyme inhibitors was not associated with 
respiratory complications or mortality after noncardiac 
surgery (19). 
Numerous studies have demonstrated that perioperative 
use of beta blockers in patients undergoing major noncardiac 
surgery reduces 30-day and 1-year mortality (20-24). In 
711 peripheral vascular surgery patients, perioperative beta 
blocker withdrawal was associated with a 2.7 times higher 
1-year mortality while continuation of beta blockers reduced 
1-year mortality 60% (24). In another study of 140 patients 
undergoing vascular surgery receiving perioperative beta 
blockers, 8 patients discontinued them postoperatively (25). 
Postoperative mortality was 50% in the patients who stopped 
beta blockers versus 1.5% in the patients who continued 
beta blockers (25).
Commonly used drugs for management of postoperative 
surgica l  hypertens ion inc lude  adminis trat ion of 
intravenous nitroglycerin, sodium nitroprusside, beta 
blockers, hydralazine, and calcium channel blockers 
including clevidipine (26,27). Clevidipine is a rapid-acting, 
dihydropyridine L-type calcium channel blocker with a 
half-life of about 1 minute that reduces arterial pressure by 
direct arterial vasodilation with selective action on arteriolar 
resistance vessels and does not cause reflex tachycardia 
and tachyphylaxis (27). Its favorable pharmacodynamic 
and pharmacokinetic properties cause clevidipine to be 
an effective and safe drug for treating acute perioperative 
hypertension (26,27). A systematic review and meta-analysis 
concluded that clevidipine was the drug of choice for the 
management of acute postoperative hypertension (26). Three 
prospective, randomized, open-label, parallel comparison 
studies compared use of clevidipine to nitroglycerin or 
sodium nitroprusside perioperatively or to nicardipine 
postoperatively for acute hypertension treatment in 1,512 
cardiac surgery patients (27). There was no difference in 
the incidence of myocardial infarction, stroke, or renal 
dysfunction between clevidipine and the other three 
drugs used (27). There was no difference in mortality 
between clevidipine, nitroglycerin, and nicardipine. 
Mortality, however, was higher in sodium nitroprusside- 
treated patients than in clevidipine-treated patients (27). 
Clevidipine was also more effective than nitroglycerin or 
sodium nitroprusside in maintaining blood pressure within 
the prespecified blood pressure range and had fewer blood 
pressure excursions beyond these blood pressure limits than 
nicardipine (27). Patients with intraoperative hypertension 
should be treated with intravenous medications until they 
can resume oral medications.
Antihypertensive drug therapy should not be stopped 
abruptly (25,28,29). Withdrawal syndromes have been 
reported after abrupt cessation of beta blockers, clonidine 
hydrochloride, methyldopa, guanabenz, and bethanidine 
sulfate (28). Accelerated angina pectoris, myocardial 
infarction, or ventricular arrhythmias may occur in patients 
with coronary artery disease after abrupt cessation of 
beta blockers (25,28,29). Abrupt cessation of clonidine 
hydrochloride, methyldopa, reserpine, and guanfacine may 
cause a hyperadrenergic state with severe hypertension, 
tachycardia, anxiety, and sweating (28,29). 
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